(ZEG) AstraZeneca - Ratings and Ratios
Cancer Drugs, Heart Drugs, Lung Drugs, Diabetes Drugs, Rare Disease Drugs
ZEG EPS (Earnings per Share)
ZEG Revenue
Description: ZEG AstraZeneca
AstraZeneca PLC is a leading biopharmaceutical company that focuses on the discovery, development, manufacture, and commercialization of prescription medicines across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases.
The companys diverse product portfolio includes several blockbuster drugs such as Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Farxiga, Brilinta, and Symbicort, among others. These products are marketed globally through distributors and local representative offices in the UK, US, Europe, and Asia, serving both primary and specialty care physicians.
AstraZeneca has established strategic partnerships to drive innovation, including a collaboration with Tempus to develop a multimodal foundation model in oncology, with IonQ, Inc. for quantum-accelerated computational chemistry, and with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates. These partnerships demonstrate the companys commitment to leveraging cutting-edge technologies to improve patient outcomes.
From a financial perspective, AstraZenecas market capitalization stands at approximately €191.5 billion, with a forward P/E ratio of 15.70, indicating a relatively attractive valuation. The companys return on equity (RoE) is 19.18%, suggesting a strong ability to generate profits from shareholder equity. Other key performance indicators (KPIs) to monitor include revenue growth, R&D expenses as a percentage of sales, and operating margin expansion.
To further evaluate AstraZenecas investment potential, it is essential to analyze its pipeline, including the number of products in clinical development, regulatory approvals, and potential launches. Additionally, monitoring the companys cash flow generation, debt-to-equity ratio, and dividend yield can provide insights into its financial health and ability to return value to shareholders.
ZEG Stock Overview
| Market Cap in USD | 248,987m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
ZEG Stock Ratings
| Growth Rating | 21.6% |
| Fundamental | 81.6% |
| Dividend Rating | 44.7% |
| Return 12m vs S&P 500 | -24.2% |
| Analyst Rating | - |
ZEG Dividends
| Dividend Yield 12m | 2.47% |
| Yield on Cost 5y | 3.91% |
| Annual Growth 5y | 1.58% |
| Payout Consistency | 96.7% |
| Payout Ratio | 57.7% |
ZEG Growth Ratios
| Growth Correlation 3m | 48.7% |
| Growth Correlation 12m | -36.2% |
| Growth Correlation 5y | 84.5% |
| CAGR 5y | 10.20% |
| CAGR/Max DD 5y | 0.36 |
| Sharpe Ratio 12m | 0.74 |
| Alpha | -16.92 |
| Beta | 0.104 |
| Volatility | 20.82% |
| Current Volume | 14.5k |
| Average Volume 20d | 9.5k |
| Stop Loss | 132.7 (-3.1%) |
| Signal | 0.19 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (8.29b TTM) > 0 and > 6% of Revenue (6% = 3.39b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.14% (prev -6.46%; Δ -1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 13.39b > Net Income 8.29b (YES >=105%, WARN >=100%) |
| Net Debt (25.78b) to EBITDA (18.29b) ratio: 1.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.56b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 81.38% (prev 82.08%; Δ -0.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.13% (prev 47.09%; Δ 5.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.76 (EBITDA TTM 18.29b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 0.86
| (A) -0.04 = (Total Current Assets 28.94b - Total Current Liabilities 33.54b) / Total Assets 112.42b |
| (B) 0.06 = Retained Earnings (Balance) 7.02b / Total Assets 112.42b |
| (C) 0.12 = EBIT TTM 12.98b / Avg Total Assets 108.38b |
| (D) 0.11 = Book Value of Equity 7.41b / Total Liabilities 67.61b |
| Total Rating: 0.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.56
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 2.99% = 1.50 |
| 3. FCF Margin 14.48% = 3.62 |
| 4. Debt/Equity 0.71 = 2.26 |
| 5. Debt/Ebitda 1.73 = 0.53 |
| 6. ROIC - WACC 8.85% = 11.07 |
| 7. RoE 19.84% = 1.65 |
| 8. Rev. Trend 94.91% = 4.75 |
| 9. Rev. CAGR 10.51% = 1.31 |
| 10. EPS Trend 52.01% = 1.30 |
| 11. EPS CAGR 15.72% = 1.57 |
What is the price of ZEG shares?
Over the past week, the price has changed by -1.72%, over one month by +10.82%, over three months by +10.96% and over the past year by -10.80%.
Is AstraZeneca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZEG is around 118.55 EUR . This means that ZEG is currently overvalued and has a potential downside of -13.4%.
Is ZEG a buy, sell or hold?
What are the forecasts/targets for the ZEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 129 | -5.8% |
ZEG Fundamental Data Overview
Market Cap USD = 248.99b (213.76b EUR * 1.1648 EUR.USD)
CCE Cash And Equivalents = 7.11b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.9127
P/E Forward = 17.2712
P/S = 3.7833
P/B = 5.5693
P/EG = 1.0222
Beta = 0.146
Revenue TTM = 56.50b USD
EBIT TTM = 12.98b USD
EBITDA TTM = 18.29b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 6.85b USD (from shortTermDebt, last quarter)
Debt = 31.57b USD (Calculated: Short Term 6.85b + Long Term 24.71b)
Net Debt = 25.78b USD (from netDebt column, last quarter)
Enterprise Value = 273.45b USD (248.99b + Debt 31.57b - CCE 7.11b)
Interest Coverage Ratio = 7.76 (Ebit TTM 12.98b / Interest Expense TTM 1.67b)
FCF Yield = 2.99% (FCF TTM 8.18b / Enterprise Value 273.45b)
FCF Margin = 14.48% (FCF TTM 8.18b / Revenue TTM 56.50b)
Net Margin = 14.68% (Net Income TTM 8.29b / Revenue TTM 56.50b)
Gross Margin = 81.38% ((Revenue TTM 56.50b - Cost of Revenue TTM 10.52b) / Revenue TTM)
Tobins Q-Ratio = 36.90 (Enterprise Value 273.45b / Book Value Of Equity 7.41b)
Interest Expense / Debt = 1.39% (Interest Expense 439.0m / Debt 31.57b)
Taxrate = 18.99% (from yearly Income Tax Expense: 1.65b / 8.69b)
NOPAT = 10.52b (EBIT 12.98b * (1 - 18.99%))
Current Ratio = 0.86 (Total Current Assets 28.94b / Total Current Liabilities 33.54b)
Debt / Equity = 0.71 (Debt 31.57b / last Quarter total Stockholder Equity 44.72b)
Debt / EBITDA = 1.73 (Net Debt 25.78b / EBITDA 18.29b)
Debt / FCF = 3.86 (Debt 31.57b / FCF TTM 8.18b)
Total Stockholder Equity = 41.82b (last 4 quarters mean)
RoA = 7.38% (Net Income 8.29b, Total Assets 112.42b )
RoE = 19.84% (Net Income TTM 8.29b / Total Stockholder Equity 41.82b)
RoCE = 19.52% (Ebit 12.98b / (Equity 41.82b + L.T.Debt 24.71b))
RoIC = 14.66% (NOPAT 10.52b / Invested Capital 71.75b)
WACC = 5.81% (E(248.99b)/V(280.55b) * Re(6.40%)) + (D(31.57b)/V(280.55b) * Rd(1.39%) * (1-Tc(0.19)))
Shares Correlation 5-Years: 56.40 | Cagr: 0.19%
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈7.70b ; Y1≈8.73b ; Y5≈11.91b
Fair Price DCF = 133.0 (DCF Value 206.17b / Shares Outstanding 1.55b; 5y FCF grow 15.61% → 3.0% )
Revenue Correlation: 94.91 | Revenue CAGR: 10.51%
Rev Growth-of-Growth: 3.21
EPS Correlation: 52.01 | EPS CAGR: 15.72%
EPS Growth-of-Growth: 22.75